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Randall J. Lee, MD, PHDT he PREVAIL (Watchman LAA Closure Devicein Patients With Atrial Fibrillation VersusLong Term Warfarin Therapy) trial is the lat-
est in the series of studies evaluating left atrial
appendage (LAA) occlusion with the Watchman de-
vice (Boston Scientiﬁc, Natick, Massachusetts) as an
alternative to warfarin therapy for the prevention of
stroke in patients with nonvalvular atrial ﬁbrillation
(NVAF). The PREVAIL trial was initially designed as a
follow-up study to PROTECT AF (Watchman Left
Atrial Appendage Closure Technology for Embolic Pro-
tection in Patients With Atrial Fibrillation), which
demonstrated noninferiority to warfarin in preventing
stroke (1). However, the U.S. Food and Drug Adminis-
tration (FDA) raised concerns regarding acute safetySEE PAGE 1events and the selection of low stroke risk patients
(CHADS2 score of 1). In addition, many patients in
PROTECT AF were treated with chronic clopidogrel
and/or remained onwarfarin>45 days after device im-
plantation. Thus, at the request of the FDA, the PRE-
VAIL study was designed to address the limitations
of PROTECT AF and to assess the safety and efﬁcacy
of LAA occlusion for stroke prevention compared
with long-term warfarin therapy in patients with
NVAF.
Despite the limitations of PROTECT AF, the FDA
recognized the value in the study’s data. Therefore, the
FDA and the sponsor developed a Bayesian trial design
for the PREVAIL trial, taking into consideration data* Editorials published in the Journal of the American College of Cardiology
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Inc., with equity in the company.from PROTECT AF. In addition, data from PROTECT AF
continued to be collected to provide long-term safety
and effectiveness information on the LAA occlusion
device.
As discussed by Holmes et al. (2) in this issue of the
Journal, the primary endpoints for the PREVAIL trial
included: 1) the primary efﬁcacy composite of hem-
orrhagic or ischemic stroke, systemic embolism, and
cardiovascular/unexplained death; 2) the late-
ischemic efﬁcacy composite of ischemic stroke or
systemic embolism, excluding the ﬁrst 7 days after
randomization; and 3) the early safety composite of
all-cause death, ischemic stroke, serious adverse
event, or device-/procedure-related events requiring
open cardiovascular surgery or major endovascular
intervention. The PREVAIL trial did not achieve the
pre-speciﬁed noninferiority criteria for its primary
efﬁcacy endpoint. Contributing to the failure of the
PREVAIL trial to meet its primary efﬁcacy endpoint
was the duration of the trial and the low event rate in
the control group. The PREVAIL trial did achieve its
safety endpoint, and its secondary primary endpoint
was met for rate difference but not for risk ratio.
The authors of PREVAIL should be commended,
along with all the participating investigators, not only
for their contribution to this article (2), but to the
series of Watchman studies. Taken in totality, the
Watchman studies are the ﬁrst to demonstrate, in a
prospective randomized fashion, the utility of exclu-
sion of LAA in preventing stroke in patients with
NVAF compared with warfarin. On the basis of the
efﬁcacy data from the initial PROTECT AF trial, the
improved mortality data of the 5-year follow-up from
PROTECT AF, the improved safety results of the
Continued Access PROTECT AF Registry, and the
safety data from PREVAIL, an FDA panel recently
voted 13 to 1 to approve the Watchman device for use
in patients with NVAF.
Although the Watchman studies provide the proof
of principle that LAA exclusion is effective in
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14preventing stroke in patients with NVAF, LAA device
implants should not be considered universally as a
substitute for oral anticoagulation therapy. The
newer oral anticoagulation drugs demonstrate
equivalent-to-superior beneﬁt in preventing car-
dioembolic strokes while having less bleeding risk
compared with warfarin (3–6). In a recent meta-
analysis of 4 new oral anticoagulants, all 71,683
participants included in the RE-LY (Randomized
Evaluation of Long Term Anticoagulant Therapy),
ROCKET AF (Rivaroxaban Once-daily Oral Direct
Factor Xa Inhibition Compared With Vitamin K
Antagonism for Prevention of Stroke and Embolism
Trial in Atrial Fibrillation), ARISTOTLE (Apixaban
for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation), and ENGAGE AF–TIMI
48 (Effective Anticoagulation With Factor Xa Next
Generation in Atrial Fibrillation–Thrombolysis In
Myocardial Infarction 48) trials were compared for
stroke and systemic embolic events, ischemic stroke,
hemorrhagic stroke, all-cause mortality, myocardial
infarction, major bleeding, intracranial hemorrhage,
and gastrointestinal bleeding (7). A comparison of
new high-dose oral anticoagulants versus warfarin
demonstrated: 1) signiﬁcantly reduced composite
stroke or systemic embolic events (by 19%), the
beneﬁt of which was mainly driven by a large reduc-
tion in hemorrhagic stroke; 2) a 14% nonsigniﬁcant
reduction in major bleeding, a reﬂection of decreased
intracranial hemorrhage; 3) a signiﬁcant reduction in
all-cause mortality; and 4) acknowledgment that the
drugs were similar to warfarin in the prevention of
ischemic stroke and myocardial infarction.
An analysis of lower doses of dabigatran and
edoxaban compared with warfarin demonstrated: 1)
an increase in ischemic stroke versus warfarin, which
was balanced by a large decrease in hemorrhagic
stroke; 2) a signiﬁcant reduction in all-cause mortal-
ity; 3) signiﬁcantly more myocardial infarctions; 4) a
nonsigniﬁcant reduction in major bleeding but with a
signiﬁcant reduction in intracranial hemorrhage; and
5) similar gastrointestinal bleeding (7).
The introduction of LAA exclusion devices and the
newer oral anticoagulants offers improved therapies
for preventing stroke in patients with NVAF. How-
ever, the treatment of the most vulnerable patients
who have an increased risk of both ischemic and
bleeding events, namely the elderly patient (aged $75
years), patients with a history of stroke, and those
with renal dysfunction, must thoroughly evaluate the
beneﬁts and risks of device implantation versus oral
anticoagulation therapy. The initial embolic risks
and adverse events associated with the Watchman
device implantation cannot outweigh the long-termbleeding risks of the newer oral anticoagulation
drugs. In highly skilled centers in which LAA exclu-
sion is routinely performed, the procedural risks in
elderly patients do not seem to differ from younger
patients (8). Until additional data become available
for these high-risk patients, the decision to treat them
with an LAA occlusion device instead of oral anti-
coagulation therapy should be made on the basis of
the patient’s overall health, ability to tolerate oral
anticoagulation therapy, procedural risks, and the
operator’s experience.
One group of patients who have not been sufﬁ-
ciently evaluated are those with contraindications to
oral anticoagulants. The majority of these patients
were excluded from both the Watchman studies
and the newer anticoagulant trials. Despite lower
bleeding rates with the newer anticoagulant agents,
signiﬁcant bleeding still occurs in 2% to 3% of treated
patients (3–6). Patients with a contraindication to oral
anticoagulation therapy are presently not considered
candidates for the Watchman device. Although the
results of the ASAP (ASA Plavix Feasibility Study With
Watchman Left Atrial Appendage Closure Technol-
ogy) study suggest that the Watchman device can be
safely implanted after treatment with aspirin and
clopidogrel rather than a warfarin transition, the
study was small and observational in nature (9).
Percutaneous epicardial LAA exclusion with the
LARIAT device (SentreHEART, Inc., Redwood City,
California) or minimally invasive surgery with the
AtriClip device (AtriCure, Inc., West Chester, Ohio)
have been used for LAA exclusion for patients with
contraindications to oral anticoagulants (10,11).
However, prospective, randomized studies are re-
quired to fully assess the utility of LAA exclusion
without the use of short-term oral anticoagulation
therapy in this group of patients.
Complications, such as the observed 4% thrombus
formation on the Watchman device (1,9), progression
of leak size (12), and case reports of late thrombus
formation (13), suggest the need for long-term sur-
veillance with transesophageal echocardiography
(TEE). A 45-day post-procedure TEE should be per-
formed to assess for leaks and thrombus before dis-
continuing warfarin. Longer term surveillance TEEs
at 1-year intervals should be considered if there is a
leak or a partial uncovered LAA lobe, as there have
been reports of late thrombus formation after 3 years,
in addition to lack of endothelialization of an
implanted Watchman device and the potential of
device erosion through the LAA (13,14). These obser-
vations and the fact that cardioembolic events can
arise from non-LAA origins highlight consideration of
a hybrid approach of LAA occlusion and lower doses
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15of the newer anticoagulants for the treatment of
stroke in AF patients.
PREVAIL attempted to address the learning curve
by including new operators who performed the de-
vice implantation in nearly 40% of the randomized
patients. The safety results between experienced
and new operators were similar, suggesting that the
sponsor’s training program was adequate. However,
the number of new sites was small, and cases were
performed in a controlled environment. Commer-
cialization of the Watchman device will require
similar judicious training of new operators and a
controlled rollout of the product. Proper training
is necessary to increase the safety of device im-
plantation and increase the likelihood of proper
Watchman deployment. An argument can be made
that with the introduction of any new technology,
dissemination of the therapy should be localized at“centers of excellence.” Identifying operators with
the necessary skillset to implant the Watchman
device will be paramount for the long-term success
of LAA exclusion as a treatment for stroke in AF
patients.
Despite the concerns and unanswered long-term
sequelae of device implantation, with proper patient
selection, the conclusion by Holmes et al. (2) should
be considered: LAA occlusion is a reasonable alter-
native to warfarin for stroke prevention in patients
with NVAF who do not have an absolute contraindi-
cation to short-term warfarin demonstrates the evo-
lution of stroke prevention in patients with AF.
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